JP2022506072A5 - - Google Patents
Info
- Publication number
- JP2022506072A5 JP2022506072A5 JP2021523230A JP2021523230A JP2022506072A5 JP 2022506072 A5 JP2022506072 A5 JP 2022506072A5 JP 2021523230 A JP2021523230 A JP 2021523230A JP 2021523230 A JP2021523230 A JP 2021523230A JP 2022506072 A5 JP2022506072 A5 JP 2022506072A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- epcam
- seq
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751530P | 2018-10-26 | 2018-10-26 | |
| US62/751,530 | 2018-10-26 | ||
| US201962824539P | 2019-03-27 | 2019-03-27 | |
| US62/824,539 | 2019-03-27 | ||
| US201962846297P | 2019-05-10 | 2019-05-10 | |
| US62/846,297 | 2019-05-10 | ||
| PCT/US2019/057569 WO2020086665A1 (en) | 2018-10-26 | 2019-10-23 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506072A JP2022506072A (ja) | 2022-01-17 |
| JP2022506072A5 true JP2022506072A5 (https=) | 2022-10-31 |
| JP7592009B2 JP7592009B2 (ja) | 2024-11-29 |
Family
ID=70331831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523230A Active JP7592009B2 (ja) | 2018-10-26 | 2019-10-23 | ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210403594A1 (https=) |
| EP (2) | EP4736955A2 (https=) |
| JP (1) | JP7592009B2 (https=) |
| KR (1) | KR20210095874A (https=) |
| CN (1) | CN113194985A (https=) |
| AU (1) | AU2019364400A1 (https=) |
| BR (1) | BR112021007918A2 (https=) |
| CA (1) | CA3117548A1 (https=) |
| DK (1) | DK3873512T3 (https=) |
| FI (1) | FI3873512T3 (https=) |
| HR (1) | HRP20260107T1 (https=) |
| IL (1) | IL282496A (https=) |
| LT (1) | LT3873512T (https=) |
| MX (1) | MX2021004808A (https=) |
| PL (1) | PL3873512T3 (https=) |
| RS (1) | RS67852B1 (https=) |
| SG (1) | SG11202103949SA (https=) |
| SI (1) | SI3873512T1 (https=) |
| TW (1) | TWI897855B (https=) |
| WO (1) | WO2020086665A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117500834A (zh) * | 2021-06-21 | 2024-02-02 | 百时美施贵宝公司 | 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间 |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| AR130078A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| JP2025525867A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| JP2025525880A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CA2491480A1 (en) * | 2002-07-01 | 2004-01-08 | Biogen, Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
| DE60336149D1 (de) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| CN101448853A (zh) * | 2006-03-17 | 2009-06-03 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| EP2032606B1 (en) | 2006-05-30 | 2013-11-27 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| NZ610239A (en) | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| RU2683325C2 (ru) | 2009-02-05 | 2019-03-28 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
| AU2010234335A1 (en) | 2009-04-08 | 2011-10-13 | Deutsches Krebsforschungszentrum | Amatoxin-armed target-binding moieties for the treatment of cancer |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| JP5826863B2 (ja) * | 2011-02-15 | 2015-12-02 | イミュノジェン・インコーポレーテッド | 細胞傷害性ベンゾジアゼピン誘導体 |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9790274B2 (en) * | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
| EP3177643B1 (en) * | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| KR102508023B1 (ko) * | 2014-09-03 | 2023-03-10 | 이뮤노젠 아이엔씨 | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 |
| WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| AU2015311987B2 (en) | 2014-09-03 | 2020-06-04 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| CA2979394A1 (en) * | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| IL292798A (en) | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| SMT202000614T1 (it) | 2015-06-29 | 2021-01-05 | Immunogen Inc | Coniugati di anticorpi ingegnerizzati con cisteina |
| EP3328897A1 (en) | 2015-07-31 | 2018-06-06 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES |
| PT3328894T (pt) * | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
-
2019
- 2019-10-22 TW TW108138004A patent/TWI897855B/zh active
- 2019-10-23 AU AU2019364400A patent/AU2019364400A1/en active Pending
- 2019-10-23 LT LTEPPCT/US2019/057569T patent/LT3873512T/lt unknown
- 2019-10-23 JP JP2021523230A patent/JP7592009B2/ja active Active
- 2019-10-23 EP EP26151295.8A patent/EP4736955A2/en active Pending
- 2019-10-23 DK DK19876033.2T patent/DK3873512T3/da active
- 2019-10-23 BR BR112021007918-1A patent/BR112021007918A2/pt unknown
- 2019-10-23 WO PCT/US2019/057569 patent/WO2020086665A1/en not_active Ceased
- 2019-10-23 RS RS20260229A patent/RS67852B1/sr unknown
- 2019-10-23 MX MX2021004808A patent/MX2021004808A/es unknown
- 2019-10-23 EP EP19876033.2A patent/EP3873512B1/en active Active
- 2019-10-23 SI SI201931016T patent/SI3873512T1/sl unknown
- 2019-10-23 CA CA3117548A patent/CA3117548A1/en active Pending
- 2019-10-23 HR HRP20260107TT patent/HRP20260107T1/hr unknown
- 2019-10-23 SG SG11202103949SA patent/SG11202103949SA/en unknown
- 2019-10-23 FI FIEP19876033.2T patent/FI3873512T3/fi active
- 2019-10-23 US US17/288,469 patent/US20210403594A1/en active Pending
- 2019-10-23 PL PL19876033.2T patent/PL3873512T3/pl unknown
- 2019-10-23 CN CN201980084482.4A patent/CN113194985A/zh active Pending
- 2019-10-23 KR KR1020217015710A patent/KR20210095874A/ko active Pending
-
2021
- 2021-04-20 IL IL282496A patent/IL282496A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506072A5 (https=) | ||
| JP7191134B2 (ja) | Ｉｇｆ－１ｒ抗体および癌処置のためのアドレッシングビヒクルとしてのその使用 | |
| US11219693B2 (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| AU2015250759B2 (en) | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | |
| AU2016344663B2 (en) | Composition for the treatment of IGF-1R expressing cancer | |
| WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
| JP2022008618A (ja) | Ｍｕｃ１に特異的に結合する抗体及びその用途 | |
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| TWI822740B (zh) | 抗her2雙互補位抗體-藥物結合物及使用方法 | |
| JP7579991B2 (ja) | 抗ネクチン－４抗体エキサテカンコンジュゲート | |
| JP2022512778A5 (https=) | ||
| JP2019533719A5 (https=) | ||
| TW202515623A (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| JP2019503167A (ja) | Ｃｄ３８に対する抗原結合性ポリペプチド | |
| US10400037B2 (en) | Binding molecules, especially antibodies, binding to L1CAM (CD171) | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| JP7728595B2 (ja) | 二重特異性抗体及びその用途 | |
| JP2024520188A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| JP2024523885A5 (https=) | ||
| CN117751139A (zh) | 抗Nectin-4抗体依喜替康缀合物 | |
| WO2026082125A1 (zh) | 结合folr1的抗体、含有其的药物及其应用 | |
| HK40041667A (en) | Anti-her2 biparatopic antibody-drug conjugates and methods of use | |
| HK40045878B (zh) | Igf-1r抗体及其作为定位载体用於治疗癌症的用途 |